Table 2 Basic characteristics of patients received glucocorticoid treatment in the training and validation cohort
Variables | Training cohort (n = 136) | Validation cohort (n = 68) | P value |
|---|---|---|---|
Male gender n. (%) | 108 (79.41%) | 53(77.94%) | 0.81 |
Age (yr) | 43.5(35.00–56.75) | 46.0(37.00–54.00) | 0.30 |
HBeAg + n. (%) | 83 (61.03%) | 35(51.47%) | 0.19 |
Log10 [HBV DNA] | 4.77(3.06–6.22) | 4.61(3.64–5.95) | 0.78 |
ALT (U/L) | 198.00(91.00–387.50) | 140.00(91.25–421.00) | 0.54 |
AST (U/L) | 169.00(97.50–417.75) | 136.50(90.50–242.00) | 0.07 |
GGT (U/L) | 90.00(59.00–138.75) | 109.50(61.75–180.25) | 0.17 |
AKP (U/L) | 142.50(116.00–173.75) | 142.50(117.25–182.00) | 0.95 |
TBIL (μmol/L) | 302.95(184.58–417.18) | 272.60(183.95–406.20) | 0.27 |
ALB (g/L) | 31.65(29.00–34.40) | 32.45(29.30–36.05) | 0.47 |
INR | 1.76(1.56–2.11) | 2.19(1.78–2.69) | < 0.01 |
Cr (μmol/L) | 67.00(58.25–77.75) | 65.00(53.50–73.75) | 0.15 |
WBC (× 109/L) | 7.16(4.73–9.26) | 7.17(4.42–9.70) | 0.50 |
HGB (g/L) | 125.00(114.25–140.00) | 126.50(108.75–140.75 | 0.94 |
PLT (× 109/L) | 103.00(65.00–147.50) | 123.50(73.75–165.00) | 0.11 |
HE n. (%) | 46 (33.82%) | 16(23.53%) | 0.13 |
Ascites n. (%) | 71 (52.21%) | 33(48.53%) | 0.62 |
SIRS n. (%) | 45 (33.09%) | 19(27.94%) | 0.46 |
MELD score | 21.43(18.26–24.34) | 22.20(18.47–26.66) | 0.17 |
CTP score | 10.00(9.00–11.00) | 10.00(9.00–11.00) | 0.25 |
90-day mortality | 55/136 (40.44%) | 31/68 (45.59%) | 0.48 |